Nanoligent Sl
The research and development to clinical phases of innovative cancer treatments based on protein nanoparticles.
Launch date
Employees
Market cap
-
Enterprise valuation
AUD19—29m (Dealroom.co estimates Sep 2022.)
Company register number B66970088
Cerdanyola del Vallès Catalonia (HQ)
| Date | Investors | Amount | Round |
|---|---|---|---|
N/A | Grant | ||
* | N/A | Spinout | |
N/A | Grant | ||
* | €1.0m | Seed | |
* | €2.8m | Early VC | |
| Total Funding | AUD6.5m | ||
Recent News about Nanoligent Sl
EditTech stack
Tech stackLearn more about the technologies and tools that this company uses.